Application of extracts of Chou Ling Dan in the preparation of drugs against extended-spectrum β-lactamase-producing drug-resistant bacteria

Through the extraction and isolation of the stinky pill plants, the stinky pill extract was developed, and its antibacterial activity was studied by the double-dilution method of trace broth, which solved the treatment problem of multidrug-resistant E. coli, and achieved the ultra-wide-spectrum β production - Effective inhibition of lactamase-resistant bacteria provides new drug choices for anti-resistant bacteria.

CN115887517BActive Publication Date: 2024-11-26YUNNAN UNIVERSITY OF CHINESE MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310138021.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-02-20
Publication Date
2024-11-26
Estimated Expiration
2043-02-20

AI Technical Summary

Technical Problem

In recent years, with the abuse of antibiotics, the multidrug-resistant E. coli has increased significantly in clinical practice, and the efficacy of existing antibiotics has decreased significantly. There is a lack of effective treatment methods for anti-ultra-spectrum β-lactamase-resistant bacteria.

Method used

By extracting and isolating the above-ground part of the stinky pill plant, active extracts were obtained, and their inhibitory effects on drug-resistant bacteria were studied by diluting the trace broth twice, and a stinky pill extract with antibacterial activity was developed.

Benefits of technology

The extract of cinnabar has significant antibacterial activity on ultra-wide-spectrum β-lactamase and non-ultra-spectrum β-lactamase, Escherichia coli drug-resistant bacteria, and has the prospect of developing anti-resistant bacteria drugs and inhibitory effects. Better than the traditional plant antibacterial agent berberine.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115887517B_ABST
    Figure CN115887517B_ABST
Patent Text Reader

Abstract

The present invention discloses the application of a stinky dan extract in the preparation of a drug for resisting resistant bacteria producing extended-spectrum β-lactamases. The stinky dan extract is extracted with methanol, ethanol and a fat-soluble solvent, and then obtained by extraction and chromatography. The stinky dan extract of the present invention is tested for the minimum inhibitory concentration (MIC) by a micro-broth two-fold dilution method, and experimental data show that the extract has a certain antibacterial activity against resistant Escherichia coli bacteria producing extended-spectrum β-lactamases and non-extended-spectrum β-lactamases, and has the prospect of being developed into a drug for resisting resistant bacteria.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of natural drug chemistry, and particularly relates to the preparation of a stinking dan extract and its application in antibacterial aspects, and particularly to its application in resisting extended-spectrum beta-lactamase-producing drug-resistant bacteria. Background Art

[0002] In recent years, with the long-term use and abuse of antibiotics in the treatment of clinical diseases, Escherichia coli isolated from clinical settings have shown a multidrug resistant (MDR) status. As pathogens evolve, multiple strains develop drug resistance, and the effect of antibiotics becomes worse and worse with increasing doses, and even gradually loses its efficacy. Escherichia coli's resistance to cephalosporins has increased significantly in Europe, and the combined efficacy of quinolones and aminoglycosides against Escherichia coli has also decreased significantly. Therefore, in order to address the threat posed by drug-resistant strains, scientists are urgently exploring new antibiotics and new methods to address drug resistance.

[0003] Natural medicines occupy an important position in Chinese medicinal chemistry. Traditional Chinese medicine is a treasure of medical research. Many natural products have good pharmacological and biological effects and are very effective in treating diseases. They are a hot topic in modern Chinese medicine research and have broad application prospects in new drug research and development, modernization of Chinese medicine, and development of Chinese medicine resources.

[0004] Laggera Pterodonta (DC.) Benth is a medicinal plant of the genus Hexapoda of the Asteraceae family. It is also known as lion grass, stinky leaves, and six-angled chrysanthemum. It is distributed in Yunnan, Sichuan, Tibet and other places, and is mainly produced in Yunnan Province, my country, with abundant medicinal sources. There are a lot of records of Laggera Pterodonta used by the people in Yunnan in books such as "Yunnan Chinese Herbal Medicine", "Kunming Folk Common Herbs", and "Southern Yunnan Materia Medica". It has the effect of treating colds, pharyngitis, bronchitis, malaria and other diseases. The compounds identified from this genus are mainly eucalyptane-type sesquiterpenes and flavonol compounds. So far, Laggera Pterodonta has been successfully developed as a drug for anti-inflammatory treatment of sore throat, lung heat cough, etc., but there is no systematic and clinical research on drug-resistant Escherichia coli, and there is no report on the use of Laggera Pterodonta extracts against extended-spectrum β-lactamase-resistant bacteria. Summary of the invention

[0005] The purpose of the present invention is to provide an extract of Chou Ling Dan for use in the preparation of a drug for resisting extended-spectrum β-lactamase-producing resistant bacteria, aiming to solve the problems existing in the background technology. To achieve the above purpose, the technical solution adopted by the present invention is:

[0006] The present invention concentrates, extracts and separates the aerial part of the stinking dan to obtain an active extract, and subcultures the drug-resistant Escherichia coli, studies the in vitro inhibitory effect of the stinking dan extract on drug-resistant bacteria by a microbroth two-fold dilution method, gives full play to the biodiversity of my country's natural plant resources, and develops and utilizes traditional medicine. The pharmacological activity of the active components is deeply explored, compounds with biological activity are further sought, and the application of the stinking dan extract against drug-resistant bacteria with definite efficacy, small side effects, economy, effectiveness and wide clinical application is developed.

[0007] The active ingredients of the cuauhtemone extract contain the following compounds: cuauhtemone acid, 1β-hydroxy-cuauhtemone acid, 3β-hydroxy-cuauhtemone acid, holly acid, cuauhtemone diol, cuauhtemone triol A, cuauhtemone triol B, 4-O-acetylcuauthemone 3-O-(2'-hydroxy-2'-methyl-3'-acetoxybutyrate), and 3-(2',3'-diacetoxy-2'-methylbutyryl)-cuauhtemone.

[0008] The extraction method of the xiulingdan extract is as follows: the dried xiulingdan aerial part is fully crushed, 8 times of its weight of methanol is added for cold soaking or percolation, heating reflux, ultrasonic extraction for multiple times, and the solvent is collected to obtain the primary extract.

[0009] The primary extract is then treated as follows: adding 4 times the weight of water, letting it stand and filtering to remove insoluble resin and chlorophyll, concentrating under reduced pressure to obtain a concentrated solution, adding 4 times the weight of anhydrous ethanol, letting it stand and filtering to remove insoluble matter, and evaporating the solvent to obtain a xiulingdan extract; or, subjecting the primary extract to normal phase silica gel column chromatography to remove water-soluble impurities, and then eluting with 20% to 95% ethanol, collecting the ethanol eluate, and recovering the solvent to dryness to obtain a xiulingdan extract; or, passing the primary extract solution through a polyamide column or a dextran gel column, eluting with water and 95% ethanol in turn, collecting the ethanol eluate, and recovering the solvent to dryness to obtain a xiulingdan extract.

[0010] Beneficial effects of the present invention:

[0011] The minimum inhibitory concentration (MIC) of the xiulingdan extract of the present invention is determined by the microbroth two-fold dilution method. Experimental data show that the extract has certain antibacterial activity against resistant Escherichia coli producing and non-extended-spectrum β-lactamase-producing Escherichia coli, and has the prospect of being developed into a drug against resistant bacteria. BRIEF DESCRIPTION OF THE DRAWINGS

[0012] Figure 1 This is the structural diagram of stinking dan acid.

[0013] Figure 2 This is the structure diagram of 1β-hydroxy-stindan acid.

[0014] Figure 3 This is the structural diagram of 3β-hydroxy-stindan acid.

[0015] Figure 4 This is the structure diagram of hollyic acid.

[0016] Figure 5 This is the structural diagram of stinky elixir diol.

[0017] Figure 6 This is the structural diagram of triol methyl.

[0018] Figure 7 This is the structural diagram of triol ethyl of stinky elixir.

[0019] Figure 8 This is the structure diagram of 4-O-acetyl cuauthemone 3-O-(2'-hydroxy-2'-methyl-3'-acetoxybutyrate).

[0020] Fig. 9 This is the structure diagram of 3-(2',3'-diacetoxy-2'-methylbutyryl)-cuauhtemone.

[0021] Fig.10 It is the minimum inhibitory concentration of the extract of Chou Ling Dan against different bacteria. DETAILED DESCRIPTION

[0022] In order to facilitate the understanding of the present invention, the present invention will be described more fully below with reference to the relevant drawings. The preferred embodiments of the present invention are given in the drawings. However, the present invention can be implemented in many different forms and is not limited to the embodiments described herein. On the contrary, the purpose of providing these embodiments is to make the disclosure of the present invention more thoroughly understood.

[0023] It should be noted that when an element is referred to as being "fixed to" another element, it may be directly on the other element or there may also be a centered element. When an element is considered to be "connected" to another element, it may be directly connected to the other element or there may be a centered element at the same time. On the contrary, when an element is referred to as being "directly on" another element, there is no intermediate element. The terms "vertical", "horizontal", "left", "right" and similar expressions used herein are for illustrative purposes only and are not intended to be the only implementation method. The terms "upper end", "lower end", "left side", "right side", "front end", "rear end" and similar expressions used herein are positional relationships with reference to the accompanying drawings.

[0024] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art of the present invention. The terms used herein in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention. The term "and / or" used herein includes any and all combinations of one or more related listed items.

[0025] The technical solution of this patent is further described in detail below in conjunction with specific implementation methods.

[0026] like Figures 1 to 10 As shown, the following embodiments are described in detail:

[0027] Embodiment 1: the preparation method of the extract of Chou Ling Dan.

[0028] The dried aerial part of the stinking dan was fully crushed, and 8 times of its weight of methanol was added for cold soaking or percolation, heated under reflux, and ultrasonic extraction was performed for multiple times, and the solvents were collected and combined to obtain a primary extract.

[0029] Add 4 times the mass of water, let it stand and filter out insoluble resin and chlorophyll, concentrate under reduced pressure to obtain a concentrate, add 4 times the mass of anhydrous ethanol, let it stand and filter out insoluble matter, and evaporate the solvent to obtain the extract of Xiulingdan.

[0030] Alternatively, the primary extract is subjected to normal phase silica gel column chromatography to remove water-soluble impurities, and then eluted with 20%-95% ethanol, the ethanol eluate is collected, and the solvent is recovered to dryness to obtain the choulingdan extract.

[0031] Alternatively, the initial extract solution is passed through a polyamide column or a dextran gel column, eluted with water and 95% ethanol in sequence, the ethanol eluate is collected, and the solvent is recovered to dryness to obtain the choulingdan extract.

[0032] The extract of linalool contains linalool acid, linalool acid ( Figure 1 )、1β-hydroxy-stinking acid( Figure 2 )、3β-hydroxy-stinking acid( Figure 3 )、Hydroxypropylamine( Figure 4 )、Stinking dan diol( Figure 5 )、Stinkling elixir triol methyl( Figure 6 )、Stoutelin Triol Ethyl( Figure 7 ), 4-O-acetyl cuauthemone 3-O-(2'-hydroxy-2'-methyl-3'-acetoxybutyrate) ( Figure 8 ), 3-(2',3'-diacetoxy-2'-methylbutyryl)-cuauhtemone ( Fig. 9) and other active compounds. HPLC quantitative detection showed that the content of cholingdan acid in the cholingdan extract was 15.2% and the content of holly acid was 6.1%.

[0033] The above active compounds can be obtained by the following separation methods:

[0034] The extract of the stinking dan obtained by the above method was separated by silica gel column chromatography, and the eluent was petroleum ether-acetone (12:1~100% acetone), and 8 parts A~H were obtained, among which parts A, B, and D were washed and recrystallized to obtain the above-mentioned active compounds 1, 2, and 3. The remaining mother liquor was mixed with silica gel and then chromatographed on a normal phase silica gel column, and petroleum ether-ethyl acetate (20:1~100% ethyl acetate) was added with acid (1 drop was added to 5 ml), and further separated by high performance liquid phase to obtain the above-mentioned compounds 4-9. Example

[0035] Antibacterial Experiment of Extracts from Chou Ling Dan

[0036] 1. Instruments and Materials

[0037] 1.1 Instruments: The microplate reader was purchased from Nanjing Detie Experimental Equipment Co., Ltd.; the high pressure sterilizer was purchased from Shanghai Boxun Medical Biological Instrument Co., Ltd.

[0038] 1.2 Materials: Broth liquid culture medium and broth agar culture medium were purchased from Guangdong Huankai Biotechnology Co., Ltd.; 96-well plates were purchased from Wuxi Nice Biotechnology Co., Ltd.; DMSO was produced by Tianjin Jindong Tianzheng Fine Chemical Reagent Factory.

[0039] 1.3 Strains: The strains used include common strains and drug-resistant strains (ESBL+ and ESBL-).

[0040] 1.3.1 Common strains: Escherichia coli, Staphylococcus aureus, Bacillus subtilis.

[0041] 1.3.2 Extended-spectrum β-lactamase-producing Escherichia coli (ESBL+):

[0042] USVAST-503;

[0043] USVAST-100;

[0044] 1.3.3 Non-extended-spectrum β-lactamase-producing Escherichia coli (ESBL-):

[0045] USVAST-298;

[0046] USVAST-457;

[0047] 1.3.4 The information of drug-resistant bacteria is as follows:

[0048] Table 1: Information on drug-resistant bacteria

[0049]

[0050] 1.4 Positive control drug: Pure berberine was purchased from Shanghai MacLean Biochemical Technology Co., Ltd.; Ceftriaxone Sodium Powder for Injection was purchased from Beijing Yuekang Pharmaceutical Group Co., Ltd.

[0051] 2. Determination of minimum inhibitory concentration (MIC)

[0052] All instruments used in the experiment were wrapped in newspaper, sterilized in an autoclave (120°C, 60 min), and then irradiated with an ultraviolet sterilization lamp for more than 30 min before use.

[0053] The specific method for preparing the bacterial solution concentration is as follows:

[0054] Use an inoculation loop to inoculate the bacteria on the solid culture medium, invert it and place it in a 37℃ incubator for overnight culture, take a single colony and inoculate it on the solid culture medium, repeat the above operation for three generations, pick a single colony and inoculate it in MH liquid culture medium, place it in a 37℃ incubator on a shaker to culture it in the logarithmic growth phase, centrifuge it for 10 minutes (4200r / min), discard the upper liquid culture medium, wash it with sterile saline for 3 times, and then dilute the lower precipitate with sterile saline to OD 600nm After the concentration is 0.10, dilute 1000 times for later use.

[0055] The minimum inhibitory concentration of the extract of Chou Ling Dan against drug-resistant bacteria was determined by the microbroth two-fold dilution method. The specific method is as follows:

[0056] A 96-well plate was used, and the blank control group was 10% DMSO medium + sterile saline; the negative control was 10% DMSO medium + bacterial solution; and the positive control was 10% DMSO medium + bacterial solution + positive drug.

[0057] Use columns AE of the 96-well plate as the sample group, dilute the samples and the positive drug with 10% DMSO culture medium to a concentration of 200 ug / ml, then inject 200 ul into the second well of the second row, add 100 ul of liquid culture medium to the wells after the second well, then use a pipette to aspirate 100 ul from the second well and inject it into the third well, then blow it evenly, then inject 100 ul into the fourth well, repeat the above dilution process until the 11th well, take out 100 ul and discard it.

[0058] After diluting the sample, add 100ul of sterile saline to the blank control group and add 100ul of pre-diluted bacterial solution to the remaining wells. Under this method, the sample concentrations of the 2nd to 11th wells are: 100μg / ml, 50μg / ml, 25μg / ml, 12.5μg / ml, 6.25μg / ml, 3.125μg / ml, 1.56μg / ml, 0.79μg / ml, 0.39μg / ml, 0.19μg / ml.

[0059] The 96-well plate was placed in a 37°C incubator and incubated for 16 hours. The OD was measured using an enzyme reader. 600nm value.

[0060] Each test was performed in parallel 3 times, and the minimum inhibitory concentration (MIC, ug / ml) was defined as the absence of significant bacterial growth compared with the negative control group. The results are as follows:

[0061] Table 2: Minimum inhibitory concentration of xiulingdan extract against different bacterial species

[0062]

[0063] As shown in Table 2, the extract of xiulingdan has a certain inhibitory effect on Staphylococcus aureus and Bacillus subtilis, with a minimum inhibitory concentration of 100 ug / ml. The MIC for Escherichia coli is 50 ug / ml, the minimum inhibitory concentration for non-extended-spectrum B-lactamase-producing Escherichia coli resistant bacteria is 12.5 ug / ml, and the minimum inhibitory concentration for extended-spectrum β-lactamase-producing Escherichia coli resistant bacteria is 25 ug / ml. The inhibitory effect on resistant bacteria is better than that of natural plant berberine.

[0064] The antibacterial effect of the extract of Choulingdan on drug-resistant bacteria is stronger than that of the plant antibacterial agent berberine. It has a broad-spectrum antibacterial effect and is effective against resistant Escherichia coli that produces and does not produce extended-spectrum β-lactamases. It can become a potential active component for inhibiting drug-resistant bacteria.

[0065] The above implementation modes are only used to illustrate the present invention, but not to limit the present invention. Ordinary technicians in the relevant technical field can make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, all equivalent technical solutions also belong to the scope of the present invention. The patent protection scope of the present invention should be defined by the claims.

Claims

1. The use of the extract of Xiulingdan in the preparation of drugs against drug-resistant Escherichia coli producing extended-spectrum β-lactamases and drug-resistant Escherichia coli not producing extended-spectrum β-lactamases, The preparation method of the stinky dan extract comprises the following steps: S1: The dried aerial part of the stinking dan was crushed, and then an organic solvent was added to obtain a primary extract after cold soaking or percolation, reflux heating and ultrasonic extraction to recover the solvent; S2: add 4 times the weight of water to the initial extract, let it stand and filter to remove insoluble resin and chlorophyll, concentrate under reduced pressure to obtain a concentrate, add 4 times the weight of anhydrous ethanol, let it stand and filter to remove insoluble matter, and evaporate the solvent to obtain a stinky elixir extract; Alternatively, the primary extract is subjected to normal phase silica gel column chromatography to remove water-soluble impurities, and then eluted with 20% to 95% ethanol, the ethanol eluate is collected, and the solvent is recovered to dryness to obtain the extract of Xiulingdan; Alternatively, the primary extract solution is passed through a polyamide column or a dextran gel column, eluted with water and 95% ethanol in sequence, the ethanol eluate is collected, and the solvent is recovered to dryness to obtain the choulingdan extract.

2. The use of the extract of Chou Ling Dan according to claim 1 in the preparation of a drug for resisting drug-resistant Escherichia coli producing extended-spectrum β-lactamases and drug-resistant Escherichia coli not producing extended-spectrum β-lactamases, characterized in that The active ingredients of the cuauhtemone extract contain the following compounds: cuauhtemone acid, 1β-hydroxy-cuauhtemone acid, 3β-hydroxy-cuauhtemone acid, holly acid, cuauhtemone diol, cuauhtemone triol A, cuauhtemone triol B, 4-O-acetyl cuauthemone 3-O-(2'-hydroxy-2'-methyl-3'-acetoxybutyrate), and 3-(2',3'-diacetoxy-2'-methylbutyryl)-cuauhtemone.

3. The use of the extract of Xiulingdan according to claim 2 in the preparation of a drug for resisting drug-resistant Escherichia coli producing extended-spectrum β-lactamases and drug-resistant Escherichia coli not producing extended-spectrum β-lactamases, characterized in that: The content of cholingdanic acid in the cholingdan extract is not less than 12%, and the content of hollyic acid is not less than 5%.